Huaren Pharmaceutical News

Huaren Pharmaceutical: Notice on the wholly-owned subsidiary salbutamol sulfate injection obtaining a drug registration certificate

May 21 18:56

Huaren Pharmaceutical: ZTE Certified Public Accountants (Special General Partnership) Accountants Opinions on Huaren Pharmaceutical Co., Ltd.'s response to the 2023 Annual Report Inquiry Letter

May 21 09:24

Huaren Pharmaceutical: Announcement on the response to the inquiry letter on the annual report of the Shenzhen Stock Exchange

May 21 09:24

Huaren Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders

May 16 07:06

Huaren Pharmaceutical: Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2023 Annual General Meeting of Shareholders of Huaren Pharmaceutical Co., Ltd.

May 16 07:06

Huaren Pharmaceutical: Notice on Obtaining Approval Notice for Low-Calcium Peritoneal Dialysis Solution (Lactate-G 1.5%, G 2.5%, G 4.25%)

May 14 06:52

Huaren Pharmaceutical: Notice on the delay in responding to the Shenzhen Stock Exchange Annual Report Inquiry Letter

May 14 06:52

Huaren Pharmaceutical: Announcement on the subsidiary obtaining a medical device registration certificate

May 10 02:44

Huaren Pharmaceutical: 300110 Huaren Pharmaceutical Investor Relations Management Information 20240429

Apr 29 04:26

Huaren Pharmaceutical: Notice on the Wholly-owned Subsidiary Peritoneal Dialysis Solution (Lactate-G 4.25%) Obtaining an Approval Notice for Drug Supplementation Applications

Apr 29 03:46

Huaren Pharmaceutical: Announcement on terminating the issuance of A-shares to specific targets in 2023

Apr 24 11:00

Huaren Pharmaceutical: Announcement on Cancelling the Absorption and Merger of Wholly-owned Subsidiaries

Apr 24 11:00

Huaren Pharmaceutical: Announcement on the 2023 Profit Distribution Plan

Apr 24 11:00

Huaren Pharmaceutical: Company shares held by directors, supervisors and senior management and its change management system (April 2024)

Apr 24 11:00

Huaren Pharmaceutical: Supervisory Board Rules of Procedure (April 2024)

Apr 24 11:00

Huaren Pharmaceutical: 2023 Internal Control Self-Assessment Report

Apr 24 11:00

Huaren Pharmaceutical: Related Transaction Rules (April 2024)

Apr 24 11:00

Huaren Pharmaceutical: Audit Report of ZTE Certified Public Accountants (Special General Partnership) on the Statement of Implementation of Performance Commitments of Anhui Hengxing Pharmaceutical Co., Ltd.

Apr 24 11:00

Huaren Pharmaceutical: Special opinion of the board of directors on the sole director's independence assessment

Apr 24 11:00

Huaren Pharmaceutical: 2023 Annual Report Summary

Apr 24 11:00